title: Comparative study of muromonab-CD3 (OKT3) versus daclizumab (Zenapax) in cardiac transplantation at our center.
abstract: Recent studies support the addition of new immunosuppressive drugs as cytolytic induction therapy in cardiac transplantation. We carried out a comparative study comprising 52 patients who had undergone cardiac transplantation at our center. Thirty patients received muromonab-CD3 (OKT3, Janssen-Cilag, The Netherlands) as the induction therapy, whereas 22 patients received Daclizumab (Zenapax, Hoffman-La Roche, Nutley, NJ, USA) instead. All patients received cyclosporine or tacrolimus, mycophenolate, and steroids. Over an average follow-up period of 23.21 +/- 18 months, we analyzed retrospectively the incidence of grade > or = 3A biopsy-confirmed acute rejection episodes, the presence of infectious processes at 1 and 6 months, the occurrence of significant secondary effects, and the necessity to modify the immunosuppressive therapy during the follow-up. The results suggest that daclizumab is linked to a decreased incidence of grade > or = 3A biopsy-confirmed acute rejection and to a reduced necessity to modify the immunosuppressive therapy during the medium-term follow-up.
authors.affiliation: Servicio de Cardiologia, Hospital Universitario Virgen del Rocio, Seville, Spain. aniusa@wanadoo.es
authors.forename: A
authors.initials: A
authors.lastname: Campos
authors.forename: E
authors.initials: E
authors.lastname: Lage
authors.forename: R
authors.initials: R
authors.lastname: Hinojosa
authors.forename: A
authors.initials: A
authors.lastname: Ordóñez
authors.forename: J M
authors.initials: JM
authors.lastname: Cisneros
authors.forename: S
authors.initials: S
authors.lastname: Cabezón
authors.forename: S
authors.initials: S
authors.lastname: Gómez
authors.forename: A
authors.initials: A
authors.lastname: Aguilera
authors.forename: E
authors.initials: E
authors.lastname: Arana
authors.forename: A
authors.initials: A
authors.lastname: Cayuela
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000077561:Daclizumab; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D000077561:Daclizumab